Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31164052 | 1.00 | MAPT (0.42) | MAPTHIF1AMEN1CYP3A4HPGD | |
| SCHEMBL12556949 | 0.83 | HIF1A (0.42) | MAPTHIF1AMEN1CYP3A4HPGD | |
| SCHEMBL20245771 | 0.82 | FLT1 (0.43) | MAPTHIF1AMEN1CYP3A4HPGD | |
| SCHEMBL1828589 | 0.79 | ENPP2 (0.40) | MAPTHIF1AMEN1CYP3A4HPGD | |
| SCHEMBL29954309 | 0.79 | ENPP2 (0.40) | MAPTHIF1AMEN1CYP3A4HPGD | |
| SCHEMBL16576630 | 0.79 | MEN1 (0.38) | MAPTHIF1AMEN1CYP3A4HPGD | |
| SCHEMBL15702937 | 0.77 | MAPT (0.36) | MAPTHIF1AMEN1CYP3A4HPGD | |
| SCHEMBL3784877 | 0.77 | ENPP2 (0.45) | MAPTENPP2HSD17B10 | |
| SCHEMBL17419154 | 0.77 | LIPG (0.39) | — | |
| SCHEMBL28526616 | 0.77 | TYR (0.38) | MAPTMEN1CYP3A4ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11495769-B2 | Inorganic light emitting diode and inorganic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2022-11-08 | — | — | US | claimed |
| US-20210167321-A1 | INORGANIC LIGHT EMITTING DIODE AND INORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2021-06-03 | — | — | US | claimed |
| US-20250161266-A1 | Antibacterial 4.5 Diaryl-Thiophen-2-YL Hexafluoropropan-2-OLS | DENOVAMED INC. (CA) | 2025-05-22 | — | — | US | disclosed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| EP-4504714-A1 | ANTIBACTERIAL 4,5 DIARYL-THIOPHEN-2-YL HEXAFLUOROPROPAN-2-OLS | Denovamed Inc. (CA) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023193101-A1 | ANTIBACTERIAL 4,5 DIARYL-THIOPHEN-2-YL HEXAFLUOROPROPAN-2-OLS | DENOVAMED INC. (CA) | 2023-10-12 | — | — | WO | disclosed |
| US-11495769-B2 | Inorganic light emitting diode and inorganic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2022-11-08 | — | — | US | disclosed |
| US-20210167321-A1 | INORGANIC LIGHT EMITTING DIODE AND INORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2021-06-03 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
| US-9255100-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| EP-2614063-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014201173-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| EP-2614063-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BUB1, TTBK1, BUB1B | MAPT 948/4885HIF1A 1747/4885MEN1 864/4885 |
| US-20250161266-A1 | Antibacterial 4.5 Diaryl-Thiophen-2-YL Hexafluoropropan-2-OLS | MRPL21, TLR6, TLL2 | MAPT 4766/4885HIF1A 4230/4885MEN1 3198/4885 |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | SCN7A, SCN1A, SCN5A | MAPT 3282/4885HIF1A 2451/4885MEN1 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.